Heart International最新文献_第6页

Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention. 降低经皮左心室辅助装置支持的高危经皮冠状动脉介入治疗血管和出血风险的策略。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.105

George W Vetrovec, Amir Kaki, Jason Wollmuth, Thom G Dahle

{"title":"Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention.","authors":"George W Vetrovec, Amir Kaki, Jason Wollmuth, Thom G Dahle","doi":"10.17925/HI.2022.16.2.105","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.105","url":null,"abstract":"In patients at high risk for haemodynamic instability during percutaneous coronary intervention (PCI), practitioners are increasingly opting for prophylactic mechanical circulatory support, such as the Impella® heart pump (Abiomed, Danvers, MA, USA). Though Impella-supported high-risk PCI (HRPCI) ensures haemodynamic stability during the PCI procedure, access-related complication rates have varied significantly in published studies. Reported variability in complication rates relates to many factors, including anticoagulation practices, access and closure strategy, post-procedure care and variations in event definitions. This article aims to outline optimal strategies to minimize vascular and bleeding complications during Impella-supported HRPCI based on previously identified clinical, procedural and postprocedural risk factors. Practices to reduce complications include femoral skills training, standardized protocols to optimize access, closure, anticoagulation management and post-procedural care, as well as the application of techniques and technological advances. Protocols integrating these strategies to mitigate access-related bleeding and vascular complications for Impella-supported procedures can markedly limit vascular access risk as a barrier to appropriate large-bore mechanical circulatory support use in HRPCI.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"105-111"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872781/pdf/heart-int-16-105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9213131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation. 用于房颤高清晰定位和消融的全球脉冲场系统。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.85

Paula Sanchez-Somonte, Atul Verma

{"title":"Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation.","authors":"Paula Sanchez-Somonte, Atul Verma","doi":"10.17925/HI.2022.16.2.85","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.85","url":null,"abstract":"Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation ablation. Radiofrequency ablation has been the most common source of energy used to achieve PVI until now. In recent years, cryoballoon ablation has gained popularity due to its ability to perform PVI in a 'single-shot' fashion. In both cases (radiofrequency and cryoablation), the main limitation is their inability to achieve durable lesions without causing collateral damage to adjacent structures. In contrast, pulsed electric field (PEF) ablation is a non-thermal energy source that causes cell apoptosis by applying an electric current to the tissue. Lesions created by a field of energy seem to be more contiguous than traditional ablation, and the risk of damage to adjacent tissues is largely avoided due to the properties of the tissues and electrical fields. In recent years, new catheters capable of delivering PEF have been developed and are now undergoing clinical testing. In this article, we describe a complete solution for PVI: a single multielectrode catheter with 3D mapping capabilities that can deliver PEF in a single-shot PVI fashion with targeting beyond the pulmonary veins.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"85-90"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872786/pdf/heart-int-16-85.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. 癌症相关血栓管理的过去、现在和未来综述。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.117

Randy K Ramcharitar, Louise Man, Minhaj S Khaja, Merry Ellen Barnett, Aditya Sharma

{"title":"A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.","authors":"Randy K Ramcharitar, Louise Man, Minhaj S Khaja, Merry Ellen Barnett, Aditya Sharma","doi":"10.17925/HI.2022.16.2.117","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.117","url":null,"abstract":"Venous thromboembolism (VTE) can have a significant impact on the management, quality of life and mortality of patients with cancer. VTE occurs in 5-20% of patients with cancer, and malignancy is associated with up to 25% of all VTE. It is the second leading cause of death in ambulatory patients with cancer who are receiving chemotherapy. Increased rates of cancer-associated thrombosis are attributed to improved patient survival, increased awareness, surgery, antineoplastic treatments and the use of central venous access devices. Many factors influence cancer-associated thrombosis risk and are broadly categorized into patient-related, cancer-related and treatment-related risks. Direct-acting oral anticoagulants have shown themselves to be at least as effective in preventing recurrent VTE in patients with cancer with symptomatic and incidental VTE. This has led to a change in treatment paradigms so that direct-acting oral anticoagulants are now considered first-line agents in appropriately selected patients. In this article, we review the prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis, and discuss specific factors that affect management as well as future treatment considerations.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"117-123"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870322/pdf/heart-int-16-117.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10599933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. 马伐卡坦:治疗症状性肥厚性梗阻性心肌病的一流口服心肌蛋白调节剂。

IF 0.2

Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.91

Klevin Roger L Reyes, Gizem Bilgili, Florian Rader

{"title":"Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.","authors":"Klevin Roger L Reyes, Gizem Bilgili, Florian Rader","doi":"10.17925/HI.2022.16.2.91","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.91","url":null,"abstract":"Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disease is outflow obstruction secondary to systolic narrowing of the left ventricular outflow tract from septal hypertrophy, mitral valve abnormalities and, most importantly, hyperdynamic contractility. Recent mechanistic studies have identified excessive myosin adenosine triphosphatase activation and actin-myosin cross-bridging as major underlying causes. These studies have led to the development of mavacamten, a first-in-class myosin adenosine triphosphatase inhibitor and the first specific therapy for hypertrophic obstructive cardiomyopathy. Preclinical and subsequent pivotal clinical studies have demonstrated the efficacy and safety of mavacamten. A remarkable improvement among treated patients in peak oxygen consumption, functional capacity, symptom relief and post-exercise left ventricular outflow tract gradient, along with dramatic reductions in heart failure biomarkers, suggests that this new medication will be transformative for the symptom management of hypertrophic obstructive cardiomyopathy. There is also hope and early evidence that mavacamten may delay or obviate the need for invasive septal reduction therapies. In this article, we review the current evidence for the efficacy and safety of mavacamten and highlight important considerations for its clinical use.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"91-98"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872784/pdf/heart-int-16-91.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Side Branch is the Main Determinant Factor of Bifurcation Lesion Complexity: Critical Review with a Proposal Based on Single-centre Experience. 侧支是分叉病变复杂性的主要决定因素：基于单中心经验的批判性回顾与建议

IF 1.9

Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.67

Imad Sheiban, Filippo Figini, Valeria Gasparetto, Fabrizio D'Ascenzo, Claudio Moretti, Filippo Leonardo

引用次数: 0

A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? 超薄支架药物洗脱支架的述评:越薄越好?

IF 0.2

Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.84

Maik J Grundeken, Marcel Am Beijk

引用次数: 4

Latest Advances in Transcatheter Mitral Valve Replacement. 经导管二尖瓣置换术的最新进展。

IF 0.2

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.79

Tomoya T Hinohara, Michael J Reardon, Sachin S Goel

引用次数: 2

Endoleak after Endovascular Abdominal Aortic Aneurysm Repair Treated by Bilateral Transradial Access: Case Report. 双侧经桡动脉通路治疗腹主动脉瘤腔内修复术后腔内渗漏1例。

IF 0.2

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.106

Gustavo A Samaja, Heber Tejerina Segovia, José M Escalante, Corina Biagioni, Silvana Onorato Grats

引用次数: 0

Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future. 冠状动脉血管重建与院外心脏骤停：过去、现在和未来。

IF 1.9

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.94

Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera

{"title":"Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future.","authors":"Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera","doi":"10.17925/HI.2021.15.2.94","DOIUrl":"10.17925/HI.2021.15.2.94","url":null,"abstract":"Cardiologists and the cardiac catheter laboratory have key roles to play in the management of patients after out-of-hospital cardiac arrest (OHCA). Although immediate catheter laboratory activation is the standard of care in cardiogenic shock and ST elevation myocardial infarction, the majority of patients will present without these features and with an uncertain diagnosis. Even in the latter, early assessment and invasive management may be beneficial, but this is counterbalanced by significant resource utilization, potential to cause harm and the possibility that any diagnostic or therapeutic gains are offset by a poor neurological outcome. Past consensus on the management of the OHCA patient without ST elevation or cardiogenic shock is being challenged by emerging results from new trials in this field. Further randomized trials are ongoing, and are expected to deliver robust data from over 4,000 patients, allowing us to further refine the optimal management strategy in this challenging cohort. This article describes the benefits and pitfalls of a strategy of immediate coronary angiography in these patients, examines the recently published COACT and TOMAHAWK trials in detail, and describes a framework with which to approach the patient after resuscitated OHCA, based on the available evidence to date.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"94-102"},"PeriodicalIF":1.9,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524604/pdf/heart-int-15-94.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'? XIENCE植入后短期双重抗血小板治疗:“新常态”?

IF 0.2

Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.65

Niels Mr van der Sangen, Wouter J Kikkert, José Ps Henriques, Bimmer Epm Claessen

引用次数: 1